Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model

OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) has the characteristics of high-density desmoplastic stroma, a distinctive immunosuppressive microenvironment and is profoundly resistant to all forms of chemotherapy and immunotherapy, leading to a 5-year survival rate of 9%. Our study aims to add...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Sumit, Schoonderwoerd, Mark J A, Kroonen, Jessie S, de Graaf, Ilona J, Sluijter, Marjolein, Ruano, Dina, González-Prieto, Román, Verlaan-de Vries, Matty, Rip, Jasper, Arens, Ramon, de Miranda, Noel F C C, Hawinkels, Lukas J A C, van Hall, Thorbald, Vertegaal, Alfred C O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Pancreas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554032/
https://www.ncbi.nlm.nih.gov/pubmed/35074907
http://dx.doi.org/10.1136/gutjnl-2021-324834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554032/
https://www.ncbi.nlm.nih.gov/pubmed/35074907
http://dx.doi.org/10.1136/gutjnl-2021-324834

Ejemplares similares